Leading contract research provider, Syntagon, is delighted to announce
that it has entered into a collaborative agreement with world-class
Quality Assurance (QA) expert George Köllner.
George brings with him more than 20 years’ experience from the pharma
industry. He has served as Director of Quality Assurance at AstraZeneca
where he led the development and implementation of modern Quality
Assurance systems in API Process Development.
“I am very excited having George on our team, it will allow us to better
serve our customers by strategically setting the quality levels best
suited for the project and thus avoiding costly delays,” says Ulrika
Burén, Syntagon QA Officer.
In addition to overseeing GMP projects, George’s expertise will be
available as a stand-alone service – from quality consulting to setting
up internal quality systems and performing external audits.
Syntagon is confident that George’s competences will further strengthen
the company’s offering and improve service quality.
Syntagon sees that regulatory requirements for clinical materials are
becoming increasingly demanding, and quality requirements becoming
especially stringent in Phase II and III projects.
The company’s approach is simple: putting customers’ needs first, and
restructuring the business to increase the quality of our service.
Syntagon’s Swedish site continues to focus on regulatory support and
quality assurance as well as customer relations and project management.
Product manufacturing and manufacturing support will also remain in
Sweden.
At its facility in Latvia, the company will focus on clinical
development of production methods for drug substances, quality control
and preclinical supply.
The result of these changes will see a significant increase in the
quality of services while retaining the competitive price points
Syntagon offers today.
For more about Syntagon, visit our website at www.syntagon.com,
or follow us on Twitter at http://twitter.com/Syntagon.
This information was brought to you by Cision http://www.cisionwire.com

Add GEN to your Inbox FREE!
Subscribe today to our complimentary e-Newsletters and stay abreast of the latest biotech news and trends.